tingenin b has been researched along with Skin Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aranha, ESP; da Silva, EL; da Silva, FMA; de Moraes, MEA; de Sousa, LB; de Vasconcellos, MC; Koolen, HHF; Lima, ES; Mesquita, FP; Montenegro, RC; Rocha, WC | 1 |
| Alves, APNN; Aranha, ESP; Araújo da Silva, FM; Bentes de Sousa, L; da Silva, EL; Koolen, HHF; Lima, ES; Mesquita, FP; Montenegro, RC; Portilho, AJS; Rocha, WC; Vasconcellos, MC | 1 |
2 other study(ies) available for tingenin b and Skin Neoplasms
| Article | Year |
|---|---|
22β-hydroxytingenone reduces proliferation and invasion of human melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Humans; L-Lactate Dehydrogenase; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Skin Neoplasms; Triterpenes; Wound Healing | 2020 |
22β-hydroxytingenone induces apoptosis and suppresses invasiveness of melanoma cells by inhibiting MMP-9 activity and MAPK signaling.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Humans; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Melanoma; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Signal Transduction; Skin Neoplasms; Triterpenes | 2021 |